- Home
- JHI vs SKYE Comparison
JHI vs SKYE Comparison
Compare JHI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- SKYE
- Stock Information
- Founded
- JHI 1971
- SKYE 2012
- Country
- JHI United States
- SKYE United States
- Employees
- JHI N/A
- SKYE N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- SKYE Health Care
- Exchange
- JHI Nasdaq
- SKYE Nasdaq
- Market Cap
- JHI 124.3M
- SKYE 108.3M
- IPO Year
- JHI N/A
- SKYE N/A
- Fundamental
- Price
- JHI $13.74
- SKYE $2.70
- Analyst Decision
- JHI
- SKYE Buy
- Analyst Count
- JHI 0
- SKYE 6
- Target Price
- JHI N/A
- SKYE $18.67
- AVG Volume (30 Days)
- JHI 29.5K
- SKYE 193.9K
- Earning Date
- JHI 01-01-0001
- SKYE 02-09-2025
- Dividend Yield
- JHI 6.80%
- SKYE N/A
- EPS Growth
- JHI N/A
- SKYE N/A
- EPS
- JHI 1.05
- SKYE N/A
- Revenue
- JHI N/A
- SKYE N/A
- Revenue This Year
- JHI N/A
- SKYE N/A
- Revenue Next Year
- JHI N/A
- SKYE N/A
- P/E Ratio
- JHI $12.47
- SKYE N/A
- Revenue Growth
- JHI N/A
- SKYE N/A
- 52 Week Low
- JHI $11.63
- SKYE $2.25
- 52 Week High
- JHI $13.40
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- JHI 26.75
- SKYE 25.41
- Support Level
- JHI $13.71
- SKYE $3.21
- Resistance Level
- JHI $14.45
- SKYE $3.55
- Average True Range (ATR)
- JHI 0.11
- SKYE 0.40
- MACD
- JHI -0.07
- SKYE -0.08
- Stochastic Oscillator
- JHI 6.31
- SKYE 1.93
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.